Quantcast

Latest Novacea Inc. Stories

2009-06-11 06:00:00

RICHMOND, Calif., June 11 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that the U.S. Food and Drug Administration (FDA) has informed the company that it should expect to receive formal notice of a three month extension of the review period for the new drug application (NDA) for Intermezzo(R) (zolpidem tartrate sublingual tablet). The Intermezzo(R) NDA had been assigned a Prescription Drug User Fee Act (PDUFA) date of July 30, 2009. Under this...

2009-06-09 08:00:00

Analyses of Efficacy and Absence of Rebound Effect in a Clinical Study of Intermezzo(R) (Zolpidem Tartrate Sublingual Tablet 3.5 mg) to Treat Middle-of-the-Night (MOTN) Awakening on an As-Needed Basis RICHMOND, Calif., June 9 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today...

2009-05-28 08:00:00

POINT RICHMOND, Calif., May 28 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the 8th Annual Needham Life Science Conference in New York City on Wednesday, June 10, 2009 at 3:00 p.m.,...

2009-05-21 08:00:00

Safety and Efficacy Study of Zolpidem Tartrate Sublingual Tablet in Treating Middle-of-the-Night Awakening on an As-Needed Basis Evaluation of Ondansetron Augmentation in the Treatment of Obsessive Compulsive Disorder RICHMOND, Calif., May 21 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience,...

2009-05-13 15:00:00

Conference call scheduled at 5:00 PM Eastern Time today RICHMOND, Calif., May 13 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience, today announced financial results for the quarter ended March 31, 2009. Glenn A. Oclassen, President and Chief Executive Officer, commented "Intermezzo(R), our lead product...

2009-05-05 08:00:00

RICHMOND, Calif., May 5 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will report results for its first quarter 2009 on Wednesday, May 13, 2009, after market close. A conference call to review the results will begin at 5:00 p.m. ET (2:00 p.m. PT) on May 13, 2009 and...

2009-04-28 08:00:00

RICHMOND, Calif., April 28 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the Bank of America and Merrill Lynch 2009 Health Care Conference in New York City on Tuesday, May 12, 2009 at 12:40 p.m., Eastern Time. An audio webcast of the presentation will be available at www.transcept.com. The audio replay of the presentation will be available at the same location through...

2009-03-25 08:00:00

PT. RICHMOND, Calif., March 25 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced the appointment of Joseph T. Kennedy to the position of Vice President, General Counsel and Secretary. In this role, Mr. Kennedy will provide legal advice to the company on matters including...

2009-03-23 15:15:00

Conference call scheduled at 5:00 PM Eastern Time today Corporate Developments - September 2008: Submitted the Intermezzo(R) new drug application (NDA) to the U.S. Food and Drug Administration (FDA) - December 2008: FDA assigned a July 30, 2009 Prescription Drug User Fee Act (PDUFA) review date to the Intermezzo(R) NDA - January 2009: Completed merger with Novacea, Inc. to create late-stage, publicly traded specialty pharmaceutical company with cash, cash equivalents and marketable...

2009-03-13 08:00:00

PT. RICHMOND, Calif., March 13 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will report results for its fourth quarter 2008 on Monday, March 23, 2009, after market close. A conference call to review the results will begin at 5:00 p.m. ET (2:00 p.m. PT) on March 23,...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related